BioAtla, Inc. (BCAB)

Overview

BioAtla, Inc. is a frontrunner in the biopharmaceutical industry, focusing on the innovation of antibody-based therapeutics aimed at combating solid tumor cancer. Established in 2007 and based in San Diego, California, the company operates at a clinical stage, dedicating its resources to developing treatments that are both specific and selective. Its therapeutic advancements are underscored by a commitment to addressing the growing need for effective cancer treatments, primarily through its pioneering work in conditionally active biologics (CABs).

Products and Services

BioAtla's pipeline is comprised of various product candidates in different stages of clinical trials, prominently featuring antibody-drug conjugates (ADCs) among other innovative therapies. Each product is designed with the goal of targeting cancer cells selectively, minimizing damage to healthy tissue and improving patient outcomes.

• Mecbotamab Vedotin (BA3011): This CAB ADC is currently in a Phase II clinical trial aimed at treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC). It epitomizes BioAtla's approach to harnessing the power of conditionally active biologics to target tumors with precision.
• Ozuriftabmab Vedotin (BA3021): Also a CAB ADC, ozuriftabmab vedotin is in Phase II clinical trials, focusing on the treatment of melanoma and squamous cell cancer of the head and neck. Its development underscores BioAtla's commitment to expanding its range of cancer treatments.
• Evalstotug (BA3071): This product is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody in Phase II clinical trials. It represents BioAtla’s exploration into immunotherapy, targeting melanoma, carcinomas, and NSCLC with the aim of engaging the patient’s own immune system to fight cancer.
• BA3182: This bispecific candidate is in the early phase of clinical trials (Phase 1) for the treatment of adenocarcinomas. It symbolizes BioAtla’s ventures into bispecific antibody development, aiming to bind two different types of antigens, potentially offering a more comprehensive approach to targeting cancer cells.
• BA3361: Currently in preclinical studies, BA3361 represents the future direction of BioAtla’s pipeline, targeting multiple tumor types with a focus on advancing towards clinical trials. This product exemplifies the company’s ongoing efforts to broaden its impact on cancer treatment through research and development.